Researchers from the University of Helsinki, Finland, developed a nasal spray that provides protection against covid-19 for at least eight hours.
Likewise, it is effective immediately after its administration. However, specialists clarify that it is a preventive treatment and not a vaccine.
The TriSb92 molecule, developed by the team, has the ability to inactivate the Spike protein of the coronavirus, which it uses to invade cells, and offers effective protection in the short term.
Protection for eight hours
According to a recently published study, and laboratory tests with animals, they showed that the molecule protects against infections for “at least eight hours, even in cases of high risk of exposure”.
Furthermore, it is effective immediately after administration.
“TriSb92 potently neutralizes SARS-CoV-2 and its variants of interest, including delta and omicron” described the authors.
And highlighted that «the intranasal administration of a modest dose of e TriSb92 (5 or 50 micrograms) eight hours before SARS-CoV-2 challenge efficiently protected 1351 mice from infection.”
Spray against covid
According to scientists, the ability to effectively inhibit all current variants is due to the fact that the molecule targets a site on the Spike protein, common to all variants.
They also believe that this characteristic indicates that future strains of SARS-CoV-2 or new coronaviruses may be susceptible to it.
The results are yet to be peer reviewed and more research is needed before the product can be used in humans.
Vaccine complement
Spray treatment nasal is not a vaccine against covid-19, but a complement to it.
“This type of molecules that prevent infec tions, or antiviral drugs, cannot replace vaccines in protecting the population against coronavirus disease,” Professor Kalle Saksela said in a statement.
This is involved in the study and other research that seeks to develop an immunizing spray against the disease.
Preventive treatment may be useful for people whose protection from vaccines is insufficient.
Depending on the epidemic situation, it can also benefit fully vaccinated people when administered before any high-risk situation.
In an interview with Gizmodo, Saksela said the technology to make the spray is “cheap and highly manufacturable,” but he doesn’t know how long it might take for the product to reach clinical trials and the market.
*The Diar Group ios América (GDA), to which El Nacional belongs, is a leading media network founded in 1991 that promotes democratic values, an independent press, and freedom of expression in Latin America through quality journalism for our audiences.
Independent journalism needs the support of its readers to continue and ensure that the uncomfortable news they don’t want you to read remains within your reach. Today, with your support, we will continue to work hard for censorship-free journalism!
Note: This article has been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here